| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
FEN1-IN-SC13 targets flap endonuclease 1 (FEN1), a structure-specific nuclease that plays a critical role in DNA replication and repair. By inhibiting FEN1, the compound disrupts DNA replication and repair processes, leading to DNA damage accumulation and cell death.
|
|---|---|
| ln Vitro |
In vitro, FEN1-IN-SC13 inhibits FEN1 nuclease activity, leading to reduced cell proliferation and increased DNA damage in cancer cells.
|
| ln Vivo |
In vivo, FEN1-IN-SC13 has not been extensively studied.
|
| Enzyme Assay |
The in vitro FEN1 inhibition assay uses purified FEN1 enzyme and a fluorogenic flap substrate.
|
| Cell Assay |
For in vitro cellular assays, cancer cells are treated with FEN1-IN-SC13, and cell viability, DNA damage markers, and apoptosis are assessed.
|
| Animal Protocol |
In vivo studies for FEN1-IN-SC13 have not been documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for FEN1-IN-SC13 are not available.
|
| Toxicity/Toxicokinetics |
Toxicology data for FEN1-IN-SC13 are not available.
|
| References | |
| Additional Infomation |
FEN1-IN-SC13 is a research compound targeting FEN1 for cancer research. It is not approved for human use.
|
| Molecular Formula |
C24H23N3O3S
|
|---|---|
| Molecular Weight |
433.52272439003
|
| Exact Mass |
433.146
|
| CAS # |
2098776-03-3
|
| PubChem CID |
162623411
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
667
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C=CC2=C1C(N(CCC)C(N2CC1C=CC=C(C=1)NC(CC1C=CC=CC=1)=O)=O)=O
|
| InChi Key |
USTMMKOHIRMBIV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23N3O3S/c1-2-12-26-23(29)22-20(11-13-31-22)27(24(26)30)16-18-9-6-10-19(14-18)25-21(28)15-17-7-4-3-5-8-17/h3-11,13-14H,2,12,15-16H2,1H3,(H,25,28)
|
| Chemical Name |
N-[3-[(2,4-dioxo-3-propylthieno[3,2-d]pyrimidin-1-yl)methyl]phenyl]-2-phenylacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~144.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3067 mL | 11.5335 mL | 23.0670 mL | |
| 5 mM | 0.4613 mL | 2.3067 mL | 4.6134 mL | |
| 10 mM | 0.2307 mL | 1.1533 mL | 2.3067 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
